AstraZeneca PLC Share Price and Company Fundamentals
Last traded: Yesterday at 6:41 PM
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; and a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Key Metrics
PE ratio
29.08
PB ratio
606.01
Dividend yield
1.64%
Beta
0.23
Market cap
£222.76B
Enterprise value
£246.81B
Company profile
| Industry / Sector | Drug Manufacturers - General / Healthcare |
|---|---|
| Full time employees | 96100 |
| Website | https://www.astrazeneca.com |
| Mailing address | 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom |
| Phone / Fax | 44 20 3749 5000 / |
Dividends
Dividend yield
1.64%
Dividend amount
£2.36
Payout ratio
47.91%
5Y Avg. yield
-%
AstraZeneca PLC paid £2.36 dividend and the ex-dividend date was 19 Feb 2026.The dividend payout ratio is 47.91%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.AZN dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of Mar 2026, following are the company executives and directors listed on AstraZeneca PLC.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Mr. Pascal Claude Roland Soriot D.V.M., M.B.A. | CEO & Executive Director | 66 | |
| Dr. Aradhana Sarin M.D. | CFO & Executive Director | 51 | |
| Ms. Pam P. Cheng | EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board | 55 | |
| Mr. Joris Silon | Head of Investor Relations | ||
| Mr. Jeffrey Pott J.D. | CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board | ||
| Dr. Ruud Dobber Ph.D. | Executive Vice-President of BioPharmaceuticals Business Unit | ||
| Dr. Susan Mary Galbraith M.D., Ph.D. | Executive Vice President of Oncology R&D | 59 | |
| Ms. Iskra Reic | Executive Vice President of International | ||
| Mr. David Fredrickson | Executive Vice-President of Oncology Haematology Business Unit | 49 | |
| Ms. Ruth March | Senior VP of Precision Medicine - R&D Oncology |
Profitability and management effectiveness
Profit margin
17.41%
Operating margin
21.59%
Return on assets
8.19%
Return on equity
22.84%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of AstraZeneca PLC is 222.76B and its enterprise value is 246.81B. The enterprise value to revenue ratio of AZN is 4.20. The enterprise value to EBITDA ratio of AZN is 12.80.
The AZN's stocks Beta value is 0.23 making it 77% less volatile compared to LSE market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
AstraZeneca PLC (LSE:AZN) Frequently Asked Questions
1. What is AstraZeneca PLC's Stock Symbol?
AstraZeneca PLC trades on LSE under the ticker symbol "AZN".
2. What is AstraZeneca PLC's stock price today?
One share of AZN stock can currently be purchased for approximately £14364.
3. How can I contact AstraZeneca PLC?
AstraZeneca PLC's mailing address is 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom. The company can be reached via phone at 44 20 3749 5000.
4. What is AstraZeneca PLC's official website?
The official website of AstraZeneca PLC is https://www.astrazeneca.com.